A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas. (NCT05007639), a registered phase not stated study. The primary outcome is Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme..

2. Clinical Question

The programme’s broad aim was to improve initial diagnosis and assessment of STS by reaching professionals outside specialist oncology practice. The registry describes activity across the four regions of the Cancéropôle du Grand Sud-Ouest: Aquitaine, Languedoc-Roussillon, Limousin and Midi-Pyrénées. The described patient eligibility, however, refers to Aquitaine and Midi-Pyrénées. The record does not explain the relationship between these regional programme areas and the patient recruitment districts in greater detail.

The clinical question is about a care process, not a direct measure of tumour control, survival or another patient health outcome. The primary endpoint assesses whether a specified imaging step took place before surgery among patients with deep tumours. The registry record does not report the endpoint result, so the observed adherence rate and any change across periods are not known from this record.

3. Trial Design

The record describes a public health intervention programme intended to improve the initial management of STS. It lists a programme arm and a no-programme arm, and separately describes patients diagnosed before, during and after implementation. The timing-based patient groups are not randomized assignments. The record states that allocation was not stated and cautions that the arms are not a like-for-like control comparison.

The before-implementation group includes eligible patients diagnosed between 1 November 2006 and 31 December 2007. The during-implementation group includes patients diagnosed between 1 January 2008 and 31 October 2008. The after-implementation group includes patients diagnosed between 1 November 2008 and 31 December 2009. The latter two groups are described as using the same eligibility criteria as the before group. The record specifies adult patients with primary STS of any stage in Aquitaine and Midi-Pyrénées; its description of exclusions is truncated, so the complete eligibility rules are not reported in the registry record.

The intervention was directed at professionals who might suspect or diagnose STS, with the stated goal of improving initial care. The registry record does not provide further detail about the programme’s specific activities, how consistently they were delivered, or how professional exposure was assessed. The overall enrollment is 274, but group-specific enrollment and the number analyzed for the primary endpoint are not reported in the registry record.

The study is marked completed. The listed primary outcome is adherence to imaging guidance for patients with a deep tumour, assessed at surgery. The outcome title identifies the before-implementation period; the record does not report a primary outcome estimate or a statistical comparison across the time periods. It lists four outcome measures, but the other three are not described in the available record. The study start and primary completion dates are recorded as 2006-11-02 and 2011-12-31.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Participants analyzed : patients with a deep tumor

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme., measured over Assessed at surgery.

The primary endpoint concerns adherence to an imaging criterion among patients with a deep sarcoma tumour. Under the registry’s definition, imaging is compliant if the patient received magnetic resonance imaging (MRI) or a scan of the tumour zone before surgery. The adherence rate is defined as the number of patients meeting that criterion among patients with a deep tumour. The outcome is assessed at surgery, and its unit is participants.

This is a process-of-care measure: it records whether a specified diagnostic imaging step occurred at the required point in the care pathway. Such measures can be useful when an intervention is designed to influence clinical practice, because they assess whether care followed a defined recommendation rather than measuring a downstream health outcome. In this study, the endpoint focuses specifically on imaging before surgery for deep tumours; it does not, by itself, measure the quality of the imaging interpretation, whether the findings changed care, or patient outcomes.

The endpoint title refers to patients diagnosed before implementation. The registry record does not report the adherence count, denominator, rate, uncertainty interval, or an estimate comparing periods. It also does not explain in the available description how missing imaging information was handled or how the deep-tumour category was determined. Therefore, the definition is available, but the observed endpoint result and its precision are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a binary process outcome: whether a patient with a deep tumour met the imaging criterion before surgery. It defines adherence using MRI or a scan of the tumour zone, and defines the rate using compliant patients among patients with a deep tumour. These details describe the outcome, but do not establish which statistical analysis was used to estimate it. The analysis method and primary endpoint results are not reported in the registry record.

What does a binary outcome represent?

In general, a binary outcome classifies each eligible observation into one of two categories, such as meeting or not meeting a defined criterion. A proportion summarizes how often one category occurs among observations with the relevant outcome information. For this endpoint, the criterion is compliant imaging before surgery. The interpretation of a proportion depends on having a clear numerator and denominator, consistent outcome ascertainment, and an explicit account of observations with missing information. The registry record gives the intended denominator as patients with a deep tumour, but does not report the observed counts or missing-data handling.

In general, a confidence interval expresses the statistical uncertainty around an estimated quantity under the assumptions of the method used. It is not a guarantee that the true value lies within the interval, and it does not address bias caused by measurement, selection or confounding. No confidence interval for the primary endpoint is reported in the registry record. Without an estimate and its interval, readers cannot assess the precision of the adherence rate from the posted results.

What does the timing-based comparison allow?

The described groups correspond to diagnosis before, during and after programme implementation. In general, a comparison across periods can describe how an outcome varies over time, but it does not automatically isolate the programme’s effect. Other changes occurring over time, differences in the patients included, or changes in clinical practice may contribute to an observed difference. Random allocation is not stated, and the record explicitly cautions that the arms are not a like-for-like control comparison. The registry record does not report an adjustment strategy, a model, or a detailed analysis plan for addressing temporal or group differences.

A before-and-after design can be informative when the timing, population, outcome definition and measurements are well documented. Interpretation is stronger when the analysis explains how it handles changes in the composition of the groups and other concurrent influences. These are general considerations, not reported methods for this study. The registry record does not report whether these issues were assessed or addressed, nor whether the intervention’s reach or implementation was measured.

How should the planning illustrations be read?

In general, a sample-size calculation uses assumptions about the outcome, the effect to be detected, the significance level, allocation and analysis method. The record describes planning illustrations based on a stated fraction of the observed effect, with a two-sided significance level of 0.05, equal allocation and a normal approximation. It distinguishes calculations expressed as participants per arm from time-to-event calculations expressed as total events; the primary endpoint is not described as time-to-event.

These calculations are illustrations for planning, not observed power. They do not tell readers how likely this completed study was to detect an effect, and they do not demonstrate that an effect was present. Any sample-size estimate depends on its assumptions, including the effect size used. The registry record does not report the study’s own sample-size justification, and the planning assumptions should not be mistaken for the original design rationale. No new sample-size estimate or effect calculation can be made from the endpoint information reported.

What analysis details are not available?

The registry record does not report a statistical test, model specification, covariate adjustment, confidence interval method, missing-data procedure, or analysis population for the primary endpoint. It lists four outcome measures but does not provide details for the other three in the available record. The record also lists zero analyses. This absence means the posted information does not support a reconstruction of the sponsor’s statistical analysis or an independent check of a reported primary result.

For a process outcome, transparent reporting would ordinarily make clear how patients with deep tumours were identified, how imaging compliance was determined, how unavailable records were treated, and which time period or periods entered each estimate. These are general reporting considerations, not claims about what was or was not done in practice beyond the registry information. In this record, the operational definition is stated, but the results and analysis details needed to judge their precision and comparability are not reported.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Patients Diagnosed BEFORE Implementation of the Pu")
n      <- c(178)
events <- c(145)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Patients Diagnosed BEFORE Implementation of the Pu  178  145  81.5  75.0  86.9  75.1  86.5  75.1  86.5

11. Multiplicity, Missing Data and Analysis Populations

The record lists four outcome measures but identifies only the primary outcome in the available information. The other outcomes, their definitions and their analysis results are not reported in the registry record. It therefore is not possible to tell how many outcomes were tested, whether outcomes were analyzed at multiple time points, or whether a hierarchy was used to distinguish confirmatory from exploratory questions.

In general, multiplicity arises when several statistical questions are assessed. If many tests are interpreted without an appropriate plan, the chance of at least one apparently notable result can increase. Methods for addressing multiplicity depend on the research questions and analysis plan. The registry record does not report a multiplicity adjustment, a prespecified testing hierarchy, or a statistical analysis plan, so no conclusion can be drawn about how multiple outcomes or comparisons were handled.

Missing-data methods are also not reported. The endpoint definition identifies patients with deep tumours as the denominator, but the record does not give the number with missing or unassessable imaging information or describe whether such patients were excluded, classified in a particular way, or handled by another method. In general, missing outcome information can affect both the estimated rate and its uncertainty, especially if its occurrence is related to patient characteristics or care.

The analysis population is not reported in sufficient detail to determine how many patients contributed to the primary endpoint or how eligibility, exclusions and available records shaped that group. Overall enrollment is 274, but that figure does not identify the endpoint denominator. The record does not report whether every eligible patient was analyzed, how deviations from eligibility were treated, or whether analyses used different populations for different outcomes. These omissions limit assessment of the completeness and comparability of the reported evidence; in this case, the endpoint results themselves are not reported.

12. What the Result Does, and Does Not, Mean

The study addresses a relevant process question: whether patients with deep STS received specified imaging before surgery, as defined by the registry. The programme was intended to improve initial management by engaging professionals who might suspect or diagnose STS. The endpoint definition makes that particular care step clear, but the registry record does not report the observed adherence rate.

Without endpoint counts or an estimate, the posted information cannot show how commonly the imaging criterion was met before implementation. It also cannot show whether adherence changed during or after implementation, or how precise any such change might be. The record’s enrollment figure does not substitute for an endpoint denominator, since the endpoint applies to patients with deep tumours and the group-specific counts are not reported.

Even if a difference between periods were available, the timing-based groups would not by themselves establish that the programme caused the difference. The registry does not describe randomized allocation and warns that the arms are not a like-for-like control comparison. General causal interpretation would need to account for other temporal changes and differences among groups; the registry record does not report whether an analysis did so.

The endpoint is a measure of care process, not a direct measure of survival, local disease control, or patient well-being. It cannot establish whether imaging results were interpreted correctly or whether a particular imaging decision improved an individual patient’s outcome. The programme rationale discusses potential consequences of inadequate initial care, but rationale is not a study result. No medical decision or recommendation should be inferred from the information recorded.

In short, the registry describes an intervention objective, diagnosis periods and a specific imaging-adherence measure. It does not provide the outcome evidence needed to estimate adherence or evaluate change. The appropriate interpretation is therefore limited to the study question and design as recorded, with the effect and its uncertainty not reported in the registry record.

13. Why This Trial Matters Statistically

This study is statistically notable for asking whether a public health programme aimed at professional practice corresponds with a change in a defined care process. That kind of question differs from a randomized treatment comparison: the intervention is directed at the health-care environment, and the described patient groups are distinguished by diagnosis period. Understanding the design is essential before interpreting any apparent change as an intervention effect.

The primary endpoint is operationalized in a way that can be assessed for individual patients: MRI or a scan of the tumour zone before surgery among patients with a deep tumour. A clearly defined process measure can make a broad programme objective more measurable. At the same time, its interpretation depends on complete and comparable ascertainment across periods, and on knowing which patients entered the denominator. Those group-specific counts and the endpoint result are not reported in the registry record.

The record also illustrates why a study’s stated motivation and its statistical evidence must be kept separate. The background explains concerns about initial STS management; it does not establish that the intervention changed practice. To evaluate that question, readers need reported estimates, uncertainty, analysis methods and enough design detail to assess alternative explanations. Those details are not available for the primary endpoint in this record.

Finally, planning calculations and observed findings answer different questions. A planning illustration based on an observed effect can help express hypothetical future sample requirements under specified assumptions. It is not an estimate of what the completed study found, nor evidence of observed power. Keeping this distinction clear is particularly important when the registry record does not report the outcome estimate itself.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the available registry information is that it does not report primary endpoint results. Without the compliant-imaging count, denominator, rate or uncertainty interval, the central outcome cannot be quantified. The overall enrollment of 274 does not show how many participants had deep tumours or contributed to that outcome.

The comparison is based on diagnosis periods around implementation rather than stated random assignment. The registry cautions that the arms are not a like-for-like control comparison. This limits causal interpretation of any between-period difference, were one reported. The record does not describe an adjustment strategy or report whether changes over time, differences in group composition, or other influences were considered.

Programme implementation and exposure are not described in detail. The record states that the programme targeted general practitioners, treating physicians and non-specialist surgeons, but does not report the specific activities, their reach, or how implementation was assessed. The relationship between the four programme regions and the two patient recruitment districts is not further explained in the available description.

The available eligibility text is incomplete: its description of exclusions ends before the full criteria are stated. Group-specific enrollment, the primary analysis population, missing-data handling and statistical methods are not reported. Although four outcome measures are listed, only the primary measure is described. These gaps prevent a full assessment of selection, measurement, missingness and multiplicity. They are limitations of what the registry record reports and should not be taken as proof that particular procedures were absent from the study itself.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas. — NCT05007639.
• Registry record last updated 2022-01-11; status last verified 2021-11.
• Results first posted 2022-01-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed public health intervention programme intended to improve the initial management of STS. It lists programme and no-programme arms and describes patient groups diagnosed before, during and after implementation. The comparison is not randomized as reported, and the record cautions that the arms are not like-for-like controls.

The primary outcome is adherence to an imaging criterion among patients with a deep tumour: MRI or a scan of the tumour zone before surgery. It is assessed at surgery, and the outcome title refers to the before-implementation period. The record lists four outcome measures and overall enrollment of 274.

Primary endpoint results, group-specific enrollment, analysis details and the other outcome descriptions are not reported in the registry record. Thus, the record establishes the study question and endpoint definition but does not provide the estimates needed to assess adherence or change across periods.